Today we're joined by Dr. Daniel Meyers of the University of Calgary who's here to discuss his new paper out now in the Journal of Cancer Policy. It's titled "Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets".

Industry payments: doi.org/10.1016/j.jcpo.2021.100283

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.72 Industry Payments to US Physicians for Cancer Therapeutics with Dr. Daniel Meyers

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

3.72 Industry Payments to US Physicians for Cancer Therapeutics with Dr. Daniel Meyers

Download our free app to listen on your phone